OXS 3550

Drug Profile

OXS 3550

Alternative Names: 161533 TriKE; CD16/IL 15/CD33 - Oxis Biotech; CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKes); OXIS-3550; OXS 3550 TriKE

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Minnesota
  • Developer Oxis Biotech
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Drug conjugates
  • Mechanism of Action CD33 antigen modulators; IgG receptor modulators; Interleukin 15 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical B cell lymphoma

Most Recent Events

  • 01 Nov 2017 University of Minnesota plans a phase I/II trialfor Haematological malignancies (NCT03214666)
  • 31 Mar 2017 Oxis Biotech has patent protection covering methods and compositions for bi-specific targeting of cd19/cd22 in USA
  • 31 Mar 2017 Oxis Biotech has patents pending covering therapeutic compounds and its uses in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top